---
title: "Zhangzhou Pientzehuang Pharmaceutical Co.,Ltd. (600436.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600436.SH.md"
symbol: "600436.SH"
name: "Zhangzhou Pientzehuang Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:49:45.944Z"
locales:
  - [en](https://longbridge.com/en/quote/600436.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600436.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600436.SH.md)
---

# Zhangzhou Pientzehuang Pharmaceutical Co.,Ltd. (600436.SH)

## Company Overview

Zhangzhou Pientzehuang Pharmaceutical., Ltd., together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. The company offers traditional Chinese medicines and health products in various forms, including capsule, ointment, tablet, syrup, and pill; health care food and functional drinks; special efficacy cosmetics; and household chemicals under the Pien Tze Huang brand name. It is also involved in the sale of food; production of skin, hair, and oral care daily products; biotechnology and medical device research and development; sale of medical machinery; and online wholesale and retail. The company’s products are used for liver diseases, cardiovascular and cerebrovascular, cancer, cold, dermatology, and other applications.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.zzpzh.com](https://www.zzpzh.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 65 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -20.05% |  |
| Net Profit YoY | -36.64% |  |
| P/B Ratio | 5.17 |  |
| Dividend Ratio | 2.47% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 78597438698.51 |  |
| Revenue | 8592949983.89 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 12.48% | B |
| Profit Margin | 22.12% | A |
| Gross Margin | 42.18% | B |
| Revenue YoY | -20.05% | E |
| Net Profit YoY | -36.64% | D |
| Total Assets YoY | -0.54% | D |
| Net Assets YoY | -0.54% | D |
| Cash Flow Margin | 23.71% | D |
| OCF YoY | -20.05% | E |
| Turnover | 0.47 | C |
| Gearing Ratio | 14.30% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhangzhou Pientzehuang Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-20.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-36.64%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.17",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.47%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "78597438698.51",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8592949983.89",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "12.48%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "22.12%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "42.18%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-20.05%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-36.64%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.54%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.54%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "23.71%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-20.05%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.30%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 40.75 | 90/215 | 44.10 | 41.77 | 39.89 |
| PB | 5.10 | 188/215 | 8.07 | 7.37 | 6.60 |
| PS (TTM) | 9.01 | 176/215 | 11.33 | 10.90 | 9.89 |
| Dividend Yield | 2.51% | 49/215 | 2.12% | 1.88% | 1.46% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T16:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 29% |
| Overweight | 2 | 29% |
| Hold | 1 | 14% |
| Underweight | 1 | 14% |
| Sell | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 128.49 |
| Highest Target | 240.00 |
| Lowest Target | 130.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600436.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600436.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600436.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600436.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**